drugset / Trial / NCT00453102
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Zevalin may be an effective therapy for newly diagnosed marginal zone lymphoma (MZL).
Timeline
- Start
- 2006-02
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 11.1 mbq/kg | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 14.8 mbq/kg | Intravenous |
| Background | Rituximab | Monoclonal antibody | 250 mg/m2 | Intravenous |